Santen Pharmaceutical（SNPH.Y）株式概要参天製薬株式会社は、日本および海外で医薬品および医療機器の研究開発、製造、販売を行っている。 詳細SNPH.Y ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長1/6過去の実績4/6財務の健全性6/6配当金5/6報酬当社が推定した公正価値より34%で取引されている 収益は年間4.49%増加すると予測されています 過去1年間で収益は3.1%増加しました 1.99%の安定した配当金を支払う リスク分析リスクチェックの結果、SNPH.Y 、リスクは検出されなかった。すべてのリスクチェックを見るSNPH.Y Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$11.971.3% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-15b332b2016201920222025202620282031Revenue JP¥332.4bEarnings JP¥42.6bAdvancedSet Fair ValueView all narrativesSanten Pharmaceutical Co., Ltd. 競合他社OrganonSymbol: NYSE:OGNMarket cap: US$3.5bAmneal PharmaceuticalsSymbol: NasdaqGS:AMRXMarket cap: US$4.0bIndivior PharmaceuticalsSymbol: NasdaqGS:INDVMarket cap: US$4.6bPrestige Consumer HealthcareSymbol: NYSE:PBHMarket cap: US$2.3b価格と性能株価の高値、安値、推移の概要Santen Pharmaceutical過去の株価現在の株価JP¥11.9752週高値JP¥12.6852週安値JP¥9.22ベータ0.231ヶ月の変化14.34%3ヶ月変化4.27%1年変化7.21%3年間の変化33.15%5年間の変化-10.14%IPOからの変化48.95%最新ニュースお知らせ • May 12Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026.お知らせ • May 09Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 12, 2026Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 12, 2026お知らせ • Jan 08RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ ®? Mini Ophthalmic Solution 0.1%RVL Pharmaceuticals Inc. and its affiliates announced Santen Pharmaceutical Co., Ltd. ("Santen"), a leading ophthalmology company has obtained the manufacturing and marketing approval in Japan for UPNEEQ®? Mini Ophthalmic Solution 0.1% (generic name:oxymetazoline hydrochloride; development code: STN1013800; hereinafter the product), a treatment for acquired blepharoptosis (low-lying eyelids). This milestone expands access in Japan to the first approved non-invasive treatment for blepharoptosis, where treatment options have primarily been limited to surgical procedures. In the U.S. market, Upneeq®? is the first and only FDA-approved prescription eye drop for acquired blepharoptOS (low-lying eyelids), and continues to demonstrate strong patient satisfaction, increased adoption, and channel diversification. The superiority of the product was demonstrated in the primary endpoint - a change from baseline at 2 hours after administration in MRD-1 (Marginal Reflex Distance-1, the margin between the upper eyelid and the center of the pupil) at Day 14 after the start of treatment--in the once-daily group versus the placebo eye drop group. In addition, an exploratory analysis showed that improvement in MRD-1 persisted for more than 8 hours after instillation. No serious adverse effects or adverse effects leading to treatment discontinuation were observed during the study. In the Phase 3 clinical trial in Japan (once-daily instillation for 6 months), no trend toward strengthening of the eyelid-lifting effect or rebound effect was observed. In this clinical study, MRD-1 was defined as the distance from the center of the pupil to the upper eyelid margin, as determined from anterior segment photographs. Upneeq®? (oxymetazoline hydrochlorides ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis ("low-lying lids") in adults. The product was approved in the US by the FDA in July 2020. Low-lying lids may be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions. UPNEEQ is a type of medication that may affect blood pressure. Upneeq®? activates a muscle in the eyelids, lifting the lid for a more open and awake look. One drop daily is clinically proven to provide visible results in as fast as 5 minutes and lasts up to 8 hours. In July 2020, Osmotica Pharmaceuticals plc (due to a company name change, currently known as RVL Pharmaceuticals Inc.), entered into an exclusive license agreement with Santen, covering the continued development, registration, and commercialization rights for RVL-1201, a 0.1% oxymetazoline hydrochloride ophthalmic solution, in Japan and certain other international markets. Santen has been developing the product as STN1013800.お知らせ • Dec 02Santen Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 05, 2026Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 05, 2026お知らせ • Nov 07Santen Pharmaceutical Co., Ltd. Receives UK Approval for Ryjunea®? (Low-Dose Atropine 0.1 Mg/L) to Slow Progression of Childhood MyopiaSanten announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea®? (low-dose atropine 0.1 mg/ml), the first licensed treatment in the UK to slow the progression of myopia in children. The approval follows the European Commission authorisation and the first launch in Germany earlier this year, with additional launches in Europe to follow. Short-sightedness is rising fast among children in the UK, where many children now live with myopia, more than double the number from 50 years ago. Increased screen time, less outdoor activity, and intensive near work are putting a growing strain on young eyes. Globally, approximately one in three children and adolescents are expected to be affected by 2050. The first signs of myopia often appear in daily life: a child squinting to read the board, moving closer to the TV, or struggling to recognise faces at a distance. Myopia can affect learning, confidence, and participation in school and play. Early interventions are key to slowing progression and supporting children's eye health and wellbeing. Childhood myopia increases the risk of severe eye disease later in life. "A comprehensive approach, combining lifestyle habits, optical correction, and approved medical options, gives children the best chance to support healthy vision into adulthood." With over 135 years of experience in eye health, Santen is committed to advancing early intervention and collaboration in paediatric myopia, for happier lives and brighter futures. Ryjunea®? is a registered trademark of Santen Pharmaceutical Co., Ltd. Ryjunea®®? is indicated for slowing the progression of myopia in paediatric patients. Treatment may be initiated in children aged 3-14 years with a progression rate of 0.5 D or more per year and a severity of -0.5 D to -6.0 D. It is backed by the Phase III STAR study, showing that Ryjunea®? significantly reduced the annual progression of myopia with an acceptable safety and tolerability profile. As a low-dose atropine eye drop, administered once daily at bedtime, it provides a convenient way to manage myopia that integrates easily into a child's routine. The product is licensed from Sydnexis Inc. to Santen's Switzerland-based affiliate, Santen SA, for registration and commercialisation across Europe, the Middle East, and Africa (EMEA). It has received market authorisation from the European Commission on June 2, and now from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) on October 30.お知らせ • Sep 01Santen Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 06, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 06, 2025最新情報をもっと見るRecent updatesお知らせ • May 12Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026.お知らせ • May 09Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 12, 2026Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 12, 2026お知らせ • Jan 08RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ ®? Mini Ophthalmic Solution 0.1%RVL Pharmaceuticals Inc. and its affiliates announced Santen Pharmaceutical Co., Ltd. ("Santen"), a leading ophthalmology company has obtained the manufacturing and marketing approval in Japan for UPNEEQ®? Mini Ophthalmic Solution 0.1% (generic name:oxymetazoline hydrochloride; development code: STN1013800; hereinafter the product), a treatment for acquired blepharoptosis (low-lying eyelids). This milestone expands access in Japan to the first approved non-invasive treatment for blepharoptosis, where treatment options have primarily been limited to surgical procedures. In the U.S. market, Upneeq®? is the first and only FDA-approved prescription eye drop for acquired blepharoptOS (low-lying eyelids), and continues to demonstrate strong patient satisfaction, increased adoption, and channel diversification. The superiority of the product was demonstrated in the primary endpoint - a change from baseline at 2 hours after administration in MRD-1 (Marginal Reflex Distance-1, the margin between the upper eyelid and the center of the pupil) at Day 14 after the start of treatment--in the once-daily group versus the placebo eye drop group. In addition, an exploratory analysis showed that improvement in MRD-1 persisted for more than 8 hours after instillation. No serious adverse effects or adverse effects leading to treatment discontinuation were observed during the study. In the Phase 3 clinical trial in Japan (once-daily instillation for 6 months), no trend toward strengthening of the eyelid-lifting effect or rebound effect was observed. In this clinical study, MRD-1 was defined as the distance from the center of the pupil to the upper eyelid margin, as determined from anterior segment photographs. Upneeq®? (oxymetazoline hydrochlorides ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis ("low-lying lids") in adults. The product was approved in the US by the FDA in July 2020. Low-lying lids may be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions. UPNEEQ is a type of medication that may affect blood pressure. Upneeq®? activates a muscle in the eyelids, lifting the lid for a more open and awake look. One drop daily is clinically proven to provide visible results in as fast as 5 minutes and lasts up to 8 hours. In July 2020, Osmotica Pharmaceuticals plc (due to a company name change, currently known as RVL Pharmaceuticals Inc.), entered into an exclusive license agreement with Santen, covering the continued development, registration, and commercialization rights for RVL-1201, a 0.1% oxymetazoline hydrochloride ophthalmic solution, in Japan and certain other international markets. Santen has been developing the product as STN1013800.お知らせ • Dec 02Santen Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 05, 2026Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 05, 2026お知らせ • Nov 07Santen Pharmaceutical Co., Ltd. Receives UK Approval for Ryjunea®? (Low-Dose Atropine 0.1 Mg/L) to Slow Progression of Childhood MyopiaSanten announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea®? (low-dose atropine 0.1 mg/ml), the first licensed treatment in the UK to slow the progression of myopia in children. The approval follows the European Commission authorisation and the first launch in Germany earlier this year, with additional launches in Europe to follow. Short-sightedness is rising fast among children in the UK, where many children now live with myopia, more than double the number from 50 years ago. Increased screen time, less outdoor activity, and intensive near work are putting a growing strain on young eyes. Globally, approximately one in three children and adolescents are expected to be affected by 2050. The first signs of myopia often appear in daily life: a child squinting to read the board, moving closer to the TV, or struggling to recognise faces at a distance. Myopia can affect learning, confidence, and participation in school and play. Early interventions are key to slowing progression and supporting children's eye health and wellbeing. Childhood myopia increases the risk of severe eye disease later in life. "A comprehensive approach, combining lifestyle habits, optical correction, and approved medical options, gives children the best chance to support healthy vision into adulthood." With over 135 years of experience in eye health, Santen is committed to advancing early intervention and collaboration in paediatric myopia, for happier lives and brighter futures. Ryjunea®? is a registered trademark of Santen Pharmaceutical Co., Ltd. Ryjunea®®? is indicated for slowing the progression of myopia in paediatric patients. Treatment may be initiated in children aged 3-14 years with a progression rate of 0.5 D or more per year and a severity of -0.5 D to -6.0 D. It is backed by the Phase III STAR study, showing that Ryjunea®? significantly reduced the annual progression of myopia with an acceptable safety and tolerability profile. As a low-dose atropine eye drop, administered once daily at bedtime, it provides a convenient way to manage myopia that integrates easily into a child's routine. The product is licensed from Sydnexis Inc. to Santen's Switzerland-based affiliate, Santen SA, for registration and commercialisation across Europe, the Middle East, and Africa (EMEA). It has received market authorisation from the European Commission on June 2, and now from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) on October 30.お知らせ • Sep 01Santen Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 06, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 06, 2025お知らせ • Jun 06Santen Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025お知らせ • May 15Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 19,800,000 shares, representing 5.8% for ¥35,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 19,800,000 of its common shares, representing 5.8% of its outstanding shares for ¥35,000 million. The program is aimed at enhancing shareholder returns and further improving capital efficiency. The plan will be valid up to November 5, 2025. As on November 5, 2025, the company had 341,423,368 shares outstanding and 632,186 shares in its treasury.お知らせ • May 14Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025.お知らせ • Mar 06Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 13, 2025Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 13, 2025お知らせ • Dec 03Santen Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025お知らせ • Nov 07Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 5,000,000 shares, representing 1.44% for ¥10,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 of its common shares, representing 1.44% of its outstanding shares for ¥10,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan. The repurchased shares will be cancelled. The plan will be valid up to March 21, 2025. As on October 31, 2024, the company had 347,002,868 shares outstanding and 17,019,386 shares in its treasury.お知らせ • Sep 04Santen Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 07, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 07, 2024お知らせ • Jun 02Santen Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 06, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Aug 06, 2024お知らせ • May 11Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024.お知らせ • May 10+ 3 more updatesSanten Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 21,110,000 shares, representing 5.81% for ¥38,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 21,110,000 of its common shares, representing 5.81% of its outstanding shares for ¥38,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan. The repurchased shares will be cancelled. The plan will be valid up to November 6, 2024. As on March 31, 2024, the company had 363,258,785 shares outstanding and 737,469 shares in its treasury.お知らせ • Mar 02Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 09, 2024Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on May 09, 2024お知らせ • Feb 09Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. Revised Dividend guidance for the Fiscal Year Ending March 31, 2024. For the year, the company expects dividend of JPY 17.00 per share against previous guidance of JPY 16.00 per share.お知らせ • Dec 02Santen Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 08, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Feb 08, 2024お知らせ • Sep 21Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. revised consolidated earnings forecasts for the fiscal year ending March 31, 2024. For the year, on a core basis, the company expects revenue of ¥285,000 million, core operating profit of ¥50,000 million, core net profit for the year of ¥37,500 million and basic core earnings per share of ¥102.47 compared to the previous guidance of revenue of ¥273,000 million, core operating profit of ¥46,000 million, core net profit for the year of ¥34,500 million and basic core earnings per share of ¥94.27 provided earlier. On IFRS basis, the company expects revenue of ¥285,000 million, operating profit of ¥35,000 million, net profit for the year of ¥25,000 million and basic earnings per share of ¥68.34 compared to the previous guidance of revenue of ¥273,000 million, operating profit of ¥32,000 million, core net profit for the year of ¥22,400 million and basic core earnings per share of ¥61.24 provided earlier.お知らせ • Aug 27Santen Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 07, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 07, 2023お知らせ • May 31Santen Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 03, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Aug 03, 2023お知らせ • May 12+ 2 more updatesSanten Pharmaceutical Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023; Provides Dividend Guidance for the End of Second Quarter and Full Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. announced year end dividend for the year ended March 31, 2023 of JPY 16.00 per share compared to JPY 16.00 per share a year ago. Start of Distribution of Dividends (Scheduled): June 28, 2023. The company provided dividend guidance for the end of second quarter and full year ending March 31, 2024. For the end of second quarter, the company expects to pay dividend of JPY 16.00 per share compared to JPY 16.00 per share a year ago.For the year, the company expects to pay dividend of JPY 16.00 per share compared to JPY 16.00 per share a year ago.お知らせ • Feb 08Santen Pharmaceutical Co., Ltd. Revises Consolidated and Core Earnings Guidance for the Year Ending March 31, 2023Santen Pharmaceutical Co., Ltd. revised consolidated and core earnings guidance for the year ending March 31, 2023. For the year on consolidated basis, the company revised revenue of JPY 272,000 million compared to previous guidance of JPY 280,000 million. Operating loss of JPY 6,500 million compared to previous guidance operating profit of JPY 4,000 million. Net loss for the year of JPY 15,500 million compared to previous guidance of JPY 5,500 million. Basic loss per share of JPY 40.01 compared to previous guidance of JPY 14.20.For the year on core basis, the company revised revenue of JPY 272,000 million compared to previous guidance of JPY 280,000 million. Core operating profit of JPY 41,000 million compared to previous guidance JPY 45,500 million. Core Net profit for the year of JPY 30,800 million compared to previous guidance of JPY 34,100 million. Core Basic earnings per share of JPY 79.50 compared to previous guidance of JPY 88.04.お知らせ • Dec 18Santen Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 07, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Feb 07, 2023お知らせ • May 12Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023.株主還元SNPH.YUS PharmaceuticalsUS 市場7D2.0%4.9%1.0%1Y7.2%44.2%28.7%株主還元を見る業界別リターン: SNPH.Y過去 1 年間で44.2 % の収益を上げたUS Pharmaceuticals業界を下回りました。リターン対市場: SNPH.Yは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is SNPH.Y's price volatile compared to industry and market?SNPH.Y volatilitySNPH.Y Average Weekly Movement7.5%Pharmaceuticals Industry Average Movement10.1%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: SNPH.Y 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: SNPH.Yの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト18903,849Takeshi Itowww.santen.com/en参天製薬株式会社は、日本および海外で医薬品および医療機器の研究開発、製造、販売を行っています。同社の製品ポートフォリオには、プロスタグランジンF2a誘導体およびβアドレナリン受容体拮抗薬であるタフルプロスト／チモロールマレイン酸塩、緑内障および高眼圧症の治療薬として販売承認段階にあるプロスタグランジンF2a誘導体であるネタルスジルメシル酸塩およびラタノプロストなどがある。また、第3相臨床試験段階にあるプロスタグランジンアナログ点眼薬セペタプロスト、緑内障・高眼圧症治療薬として製造販売承認申請中のプロスタグランジンF2a誘導体乳剤ラタノプロストも提供している。さらに、春季性角結膜炎の治療薬として眼科用乳剤シクロスポリン、ドライアイの治療薬としてジクアホソルナトリウムを提供している。さらに、ドライアイ治療薬としてフェーズ1/2a段階にあるβ2受容体作動薬オロダテロール塩酸塩、フックス内皮角膜ジストロフィーおよびマイボーム腺機能不全の治療薬としてフェーズ2a段階にあるシロリムス点眼液を開発している；アレルギー性結膜炎の治療薬として承認申請中のヒスタミンH1受容体拮抗薬エピナスチン塩酸塩、近視治療薬として臨床第2/3相試験中の非選択的ムスカリン拮抗薬アトロピン硫酸塩、近視治療薬として臨床第2a相試験中の選択的ムスカリンM2拮抗薬AFDX0250BSがある。さらに、老眼治療薬として臨床第2a相試験中のウルソデオキシコール酸、眼瞼下垂症治療薬として臨床第3相試験中の直接作用型αアドレナリン受容体作動薬であるオキシメタゾリン塩酸塩を提供している。同社は1890年に設立され、大阪に本社を置いている。もっと見るSanten Pharmaceutical Co., Ltd. 基礎のまとめSanten Pharmaceutical の収益と売上を時価総額と比較するとどうか。SNPH.Y 基礎統計学時価総額US$3.85b収益（TTM）US$234.79m売上高(TTM)US$1.83b16.4xPER（株価収益率2.1xP/SレシオSNPH.Y は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SNPH.Y 損益計算書（TTM）収益JP¥291.62b売上原価JP¥121.88b売上総利益JP¥169.74bその他の費用JP¥132.37b収益JP¥37.37b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）116.17グロス・マージン58.21%純利益率12.81%有利子負債／自己資本比率0%SNPH.Y の長期的なパフォーマンスは？過去の実績と比較を見る配当金2.0%現在の配当利回り41%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 15:40終値2026/05/22 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Santen Pharmaceutical Co., Ltd. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18 アナリスト機関Atsushi SekiBarclaysKoichi MameganoBofA Global ResearchHidemaru YamaguchiCitigroup Inc15 その他のアナリストを表示
お知らせ • May 12Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026.
お知らせ • May 09Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 12, 2026Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 12, 2026
お知らせ • Jan 08RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ ®? Mini Ophthalmic Solution 0.1%RVL Pharmaceuticals Inc. and its affiliates announced Santen Pharmaceutical Co., Ltd. ("Santen"), a leading ophthalmology company has obtained the manufacturing and marketing approval in Japan for UPNEEQ®? Mini Ophthalmic Solution 0.1% (generic name:oxymetazoline hydrochloride; development code: STN1013800; hereinafter the product), a treatment for acquired blepharoptosis (low-lying eyelids). This milestone expands access in Japan to the first approved non-invasive treatment for blepharoptosis, where treatment options have primarily been limited to surgical procedures. In the U.S. market, Upneeq®? is the first and only FDA-approved prescription eye drop for acquired blepharoptOS (low-lying eyelids), and continues to demonstrate strong patient satisfaction, increased adoption, and channel diversification. The superiority of the product was demonstrated in the primary endpoint - a change from baseline at 2 hours after administration in MRD-1 (Marginal Reflex Distance-1, the margin between the upper eyelid and the center of the pupil) at Day 14 after the start of treatment--in the once-daily group versus the placebo eye drop group. In addition, an exploratory analysis showed that improvement in MRD-1 persisted for more than 8 hours after instillation. No serious adverse effects or adverse effects leading to treatment discontinuation were observed during the study. In the Phase 3 clinical trial in Japan (once-daily instillation for 6 months), no trend toward strengthening of the eyelid-lifting effect or rebound effect was observed. In this clinical study, MRD-1 was defined as the distance from the center of the pupil to the upper eyelid margin, as determined from anterior segment photographs. Upneeq®? (oxymetazoline hydrochlorides ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis ("low-lying lids") in adults. The product was approved in the US by the FDA in July 2020. Low-lying lids may be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions. UPNEEQ is a type of medication that may affect blood pressure. Upneeq®? activates a muscle in the eyelids, lifting the lid for a more open and awake look. One drop daily is clinically proven to provide visible results in as fast as 5 minutes and lasts up to 8 hours. In July 2020, Osmotica Pharmaceuticals plc (due to a company name change, currently known as RVL Pharmaceuticals Inc.), entered into an exclusive license agreement with Santen, covering the continued development, registration, and commercialization rights for RVL-1201, a 0.1% oxymetazoline hydrochloride ophthalmic solution, in Japan and certain other international markets. Santen has been developing the product as STN1013800.
お知らせ • Dec 02Santen Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 05, 2026Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 05, 2026
お知らせ • Nov 07Santen Pharmaceutical Co., Ltd. Receives UK Approval for Ryjunea®? (Low-Dose Atropine 0.1 Mg/L) to Slow Progression of Childhood MyopiaSanten announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea®? (low-dose atropine 0.1 mg/ml), the first licensed treatment in the UK to slow the progression of myopia in children. The approval follows the European Commission authorisation and the first launch in Germany earlier this year, with additional launches in Europe to follow. Short-sightedness is rising fast among children in the UK, where many children now live with myopia, more than double the number from 50 years ago. Increased screen time, less outdoor activity, and intensive near work are putting a growing strain on young eyes. Globally, approximately one in three children and adolescents are expected to be affected by 2050. The first signs of myopia often appear in daily life: a child squinting to read the board, moving closer to the TV, or struggling to recognise faces at a distance. Myopia can affect learning, confidence, and participation in school and play. Early interventions are key to slowing progression and supporting children's eye health and wellbeing. Childhood myopia increases the risk of severe eye disease later in life. "A comprehensive approach, combining lifestyle habits, optical correction, and approved medical options, gives children the best chance to support healthy vision into adulthood." With over 135 years of experience in eye health, Santen is committed to advancing early intervention and collaboration in paediatric myopia, for happier lives and brighter futures. Ryjunea®? is a registered trademark of Santen Pharmaceutical Co., Ltd. Ryjunea®®? is indicated for slowing the progression of myopia in paediatric patients. Treatment may be initiated in children aged 3-14 years with a progression rate of 0.5 D or more per year and a severity of -0.5 D to -6.0 D. It is backed by the Phase III STAR study, showing that Ryjunea®? significantly reduced the annual progression of myopia with an acceptable safety and tolerability profile. As a low-dose atropine eye drop, administered once daily at bedtime, it provides a convenient way to manage myopia that integrates easily into a child's routine. The product is licensed from Sydnexis Inc. to Santen's Switzerland-based affiliate, Santen SA, for registration and commercialisation across Europe, the Middle East, and Africa (EMEA). It has received market authorisation from the European Commission on June 2, and now from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) on October 30.
お知らせ • Sep 01Santen Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 06, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 06, 2025
お知らせ • May 12Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026.
お知らせ • May 09Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 12, 2026Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 12, 2026
お知らせ • Jan 08RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ ®? Mini Ophthalmic Solution 0.1%RVL Pharmaceuticals Inc. and its affiliates announced Santen Pharmaceutical Co., Ltd. ("Santen"), a leading ophthalmology company has obtained the manufacturing and marketing approval in Japan for UPNEEQ®? Mini Ophthalmic Solution 0.1% (generic name:oxymetazoline hydrochloride; development code: STN1013800; hereinafter the product), a treatment for acquired blepharoptosis (low-lying eyelids). This milestone expands access in Japan to the first approved non-invasive treatment for blepharoptosis, where treatment options have primarily been limited to surgical procedures. In the U.S. market, Upneeq®? is the first and only FDA-approved prescription eye drop for acquired blepharoptOS (low-lying eyelids), and continues to demonstrate strong patient satisfaction, increased adoption, and channel diversification. The superiority of the product was demonstrated in the primary endpoint - a change from baseline at 2 hours after administration in MRD-1 (Marginal Reflex Distance-1, the margin between the upper eyelid and the center of the pupil) at Day 14 after the start of treatment--in the once-daily group versus the placebo eye drop group. In addition, an exploratory analysis showed that improvement in MRD-1 persisted for more than 8 hours after instillation. No serious adverse effects or adverse effects leading to treatment discontinuation were observed during the study. In the Phase 3 clinical trial in Japan (once-daily instillation for 6 months), no trend toward strengthening of the eyelid-lifting effect or rebound effect was observed. In this clinical study, MRD-1 was defined as the distance from the center of the pupil to the upper eyelid margin, as determined from anterior segment photographs. Upneeq®? (oxymetazoline hydrochlorides ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis ("low-lying lids") in adults. The product was approved in the US by the FDA in July 2020. Low-lying lids may be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions. UPNEEQ is a type of medication that may affect blood pressure. Upneeq®? activates a muscle in the eyelids, lifting the lid for a more open and awake look. One drop daily is clinically proven to provide visible results in as fast as 5 minutes and lasts up to 8 hours. In July 2020, Osmotica Pharmaceuticals plc (due to a company name change, currently known as RVL Pharmaceuticals Inc.), entered into an exclusive license agreement with Santen, covering the continued development, registration, and commercialization rights for RVL-1201, a 0.1% oxymetazoline hydrochloride ophthalmic solution, in Japan and certain other international markets. Santen has been developing the product as STN1013800.
お知らせ • Dec 02Santen Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 05, 2026Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 05, 2026
お知らせ • Nov 07Santen Pharmaceutical Co., Ltd. Receives UK Approval for Ryjunea®? (Low-Dose Atropine 0.1 Mg/L) to Slow Progression of Childhood MyopiaSanten announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea®? (low-dose atropine 0.1 mg/ml), the first licensed treatment in the UK to slow the progression of myopia in children. The approval follows the European Commission authorisation and the first launch in Germany earlier this year, with additional launches in Europe to follow. Short-sightedness is rising fast among children in the UK, where many children now live with myopia, more than double the number from 50 years ago. Increased screen time, less outdoor activity, and intensive near work are putting a growing strain on young eyes. Globally, approximately one in three children and adolescents are expected to be affected by 2050. The first signs of myopia often appear in daily life: a child squinting to read the board, moving closer to the TV, or struggling to recognise faces at a distance. Myopia can affect learning, confidence, and participation in school and play. Early interventions are key to slowing progression and supporting children's eye health and wellbeing. Childhood myopia increases the risk of severe eye disease later in life. "A comprehensive approach, combining lifestyle habits, optical correction, and approved medical options, gives children the best chance to support healthy vision into adulthood." With over 135 years of experience in eye health, Santen is committed to advancing early intervention and collaboration in paediatric myopia, for happier lives and brighter futures. Ryjunea®? is a registered trademark of Santen Pharmaceutical Co., Ltd. Ryjunea®®? is indicated for slowing the progression of myopia in paediatric patients. Treatment may be initiated in children aged 3-14 years with a progression rate of 0.5 D or more per year and a severity of -0.5 D to -6.0 D. It is backed by the Phase III STAR study, showing that Ryjunea®? significantly reduced the annual progression of myopia with an acceptable safety and tolerability profile. As a low-dose atropine eye drop, administered once daily at bedtime, it provides a convenient way to manage myopia that integrates easily into a child's routine. The product is licensed from Sydnexis Inc. to Santen's Switzerland-based affiliate, Santen SA, for registration and commercialisation across Europe, the Middle East, and Africa (EMEA). It has received market authorisation from the European Commission on June 2, and now from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) on October 30.
お知らせ • Sep 01Santen Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 06, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 06, 2025
お知らせ • Jun 06Santen Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025
お知らせ • May 15Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 19,800,000 shares, representing 5.8% for ¥35,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 19,800,000 of its common shares, representing 5.8% of its outstanding shares for ¥35,000 million. The program is aimed at enhancing shareholder returns and further improving capital efficiency. The plan will be valid up to November 5, 2025. As on November 5, 2025, the company had 341,423,368 shares outstanding and 632,186 shares in its treasury.
お知らせ • May 14Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025.
お知らせ • Mar 06Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 13, 2025Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 13, 2025
お知らせ • Dec 03Santen Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025
お知らせ • Nov 07Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 5,000,000 shares, representing 1.44% for ¥10,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 of its common shares, representing 1.44% of its outstanding shares for ¥10,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan. The repurchased shares will be cancelled. The plan will be valid up to March 21, 2025. As on October 31, 2024, the company had 347,002,868 shares outstanding and 17,019,386 shares in its treasury.
お知らせ • Sep 04Santen Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 07, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 07, 2024
お知らせ • Jun 02Santen Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 06, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Aug 06, 2024
お知らせ • May 11Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024.
お知らせ • May 10+ 3 more updatesSanten Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 21,110,000 shares, representing 5.81% for ¥38,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 21,110,000 of its common shares, representing 5.81% of its outstanding shares for ¥38,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan. The repurchased shares will be cancelled. The plan will be valid up to November 6, 2024. As on March 31, 2024, the company had 363,258,785 shares outstanding and 737,469 shares in its treasury.
お知らせ • Mar 02Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 09, 2024Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on May 09, 2024
お知らせ • Feb 09Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. Revised Dividend guidance for the Fiscal Year Ending March 31, 2024. For the year, the company expects dividend of JPY 17.00 per share against previous guidance of JPY 16.00 per share.
お知らせ • Dec 02Santen Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 08, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Feb 08, 2024
お知らせ • Sep 21Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. revised consolidated earnings forecasts for the fiscal year ending March 31, 2024. For the year, on a core basis, the company expects revenue of ¥285,000 million, core operating profit of ¥50,000 million, core net profit for the year of ¥37,500 million and basic core earnings per share of ¥102.47 compared to the previous guidance of revenue of ¥273,000 million, core operating profit of ¥46,000 million, core net profit for the year of ¥34,500 million and basic core earnings per share of ¥94.27 provided earlier. On IFRS basis, the company expects revenue of ¥285,000 million, operating profit of ¥35,000 million, net profit for the year of ¥25,000 million and basic earnings per share of ¥68.34 compared to the previous guidance of revenue of ¥273,000 million, operating profit of ¥32,000 million, core net profit for the year of ¥22,400 million and basic core earnings per share of ¥61.24 provided earlier.
お知らせ • Aug 27Santen Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 07, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 07, 2023
お知らせ • May 31Santen Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 03, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Aug 03, 2023
お知らせ • May 12+ 2 more updatesSanten Pharmaceutical Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023; Provides Dividend Guidance for the End of Second Quarter and Full Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. announced year end dividend for the year ended March 31, 2023 of JPY 16.00 per share compared to JPY 16.00 per share a year ago. Start of Distribution of Dividends (Scheduled): June 28, 2023. The company provided dividend guidance for the end of second quarter and full year ending March 31, 2024. For the end of second quarter, the company expects to pay dividend of JPY 16.00 per share compared to JPY 16.00 per share a year ago.For the year, the company expects to pay dividend of JPY 16.00 per share compared to JPY 16.00 per share a year ago.
お知らせ • Feb 08Santen Pharmaceutical Co., Ltd. Revises Consolidated and Core Earnings Guidance for the Year Ending March 31, 2023Santen Pharmaceutical Co., Ltd. revised consolidated and core earnings guidance for the year ending March 31, 2023. For the year on consolidated basis, the company revised revenue of JPY 272,000 million compared to previous guidance of JPY 280,000 million. Operating loss of JPY 6,500 million compared to previous guidance operating profit of JPY 4,000 million. Net loss for the year of JPY 15,500 million compared to previous guidance of JPY 5,500 million. Basic loss per share of JPY 40.01 compared to previous guidance of JPY 14.20.For the year on core basis, the company revised revenue of JPY 272,000 million compared to previous guidance of JPY 280,000 million. Core operating profit of JPY 41,000 million compared to previous guidance JPY 45,500 million. Core Net profit for the year of JPY 30,800 million compared to previous guidance of JPY 34,100 million. Core Basic earnings per share of JPY 79.50 compared to previous guidance of JPY 88.04.
お知らせ • Dec 18Santen Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 07, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Feb 07, 2023
お知らせ • May 12Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023.
